Terms: = Ovarian cancer AND IL6ST, CDw130, 3572, ENSG00000134352, P40189, IL6R-beta, GP130-RAPS, GP130, CD130
24 results:
1. The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf CL; Pruett C; Lighter D; Jorcyk CL
Front Immunol; 2023; 14():1239732. PubMed ID: 37841259
[TBL] [Abstract] [Full Text] [Related]
2. Butein Inhibits Cell Growth by Blocking the IL-6/IL-6Rα Interaction in Human ovarian cancer and by Regulation of the IL-6/STAT3/FoxO3a Pathway.
Park SA; Seo YJ; Kim LK; Kim HJ; Yoon KD; Heo TH
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047012
[No Abstract] [Full Text] [Related]
3. Inhibition of gp130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park SA; Kim LK; Park HM; Kim HJ; Heo TH
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
[TBL] [Abstract] [Full Text] [Related]
4. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit ovarian cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract] [Full Text] [Related]
5. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
[TBL] [Abstract] [Full Text] [Related]
6. Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in ovarian Clear Cell cancer.
Azar WJ; Christie EL; Mitchell C; Liu DS; Au-Yeung G; Bowtell DDL
Cancer Res; 2020 Nov; 80(22):4960-4971. PubMed ID: 32917727
[TBL] [Abstract] [Full Text] [Related]
7. Enhanced recovery for obese patients undergoing gynecologic cancer surgery.
Harrison R; Iniesta MD; Pitcher B; Ramirez PT; Cain K; Siverand AM; Mena G; Lasala J; Meyer LA
Int J Gynecol Cancer; 2020 Oct; 30(10):1595-1602. PubMed ID: 32848023
[TBL] [Abstract] [Full Text] [Related]
8. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.
Lu T; Tang J; Shrestha B; Heath BR; Hong L; Lei YL; Ljungman M; Neamati N
Theranostics; 2020; 10(15):6959-6976. PubMed ID: 32550915
[TBL] [Abstract] [Full Text] [Related]
9. Predictive Blood-Based Biomarkers in Patients with Epithelial ovarian cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
[TBL] [Abstract] [Full Text] [Related]
10. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer.
Taher MY; Davies DM; Maher J
Biochem Soc Trans; 2018 Dec; 46(6):1449-1462. PubMed ID: 30467123
[TBL] [Abstract] [Full Text] [Related]
11. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in cancer: Challenges and Opportunities.
Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
[TBL] [Abstract] [Full Text] [Related]
12. Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Takenaka M; Saito M; Iwakawa R; Yanaihara N; Saito M; Kato M; Ichikawa H; Shibata T; Yokota J; Okamoto A; Kohno T
Int J Oncol; 2015; 46(6):2389-98. PubMed ID: 25846456
[TBL] [Abstract] [Full Text] [Related]
13. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities.
Scheller J; Garbers C; Rose-John S
Semin Immunol; 2014 Feb; 26(1):2-12. PubMed ID: 24325804
[TBL] [Abstract] [Full Text] [Related]
14. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
[TBL] [Abstract] [Full Text] [Related]
15. Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.
Ataie-Kachoie P; Morris DL; Pourgholami MH
PLoS One; 2013; 8(4):e60817. PubMed ID: 23593315
[TBL] [Abstract] [Full Text] [Related]
16. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.
Xu S; Grande F; Garofalo A; Neamati N
Mol Cancer Ther; 2013 Jun; 12(6):937-49. PubMed ID: 23536726
[TBL] [Abstract] [Full Text] [Related]
17. Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population.
Bacha OM; Gregoire J; Grondin K; Edelweiss MI; Laframboise R; Simard J; Plante M
Int J Gynecol Cancer; 2012 Jul; 22(6):974-8. PubMed ID: 22740003
[TBL] [Abstract] [Full Text] [Related]
18. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells.
Wang Y; Li L; Guo X; Jin X; Sun W; Zhang X; Xu RC
Cytokine; 2012 Aug; 59(2):228-36. PubMed ID: 22595649
[TBL] [Abstract] [Full Text] [Related]
19. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.
Landen CN; Lin YG; Armaiz Pena GN; Das PD; Arevalo JM; Kamat AA; Han LY; Jennings NB; Spannuth WA; Thaker PH; Lutgendorf SK; Savary CA; Sanguino AM; Lopez-Berestein G; Cole SW; Sood AK
Cancer Res; 2007 Nov; 67(21):10389-96. PubMed ID: 17974982
[TBL] [Abstract] [Full Text] [Related]
20. Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells.
Wang Y; Yang J; Gao Y; Du Y; Bao L; Niu W; Yao Z
Cell Mol Immunol; 2005 Oct; 2(5):365-72. PubMed ID: 16368063
[TBL] [Abstract] [Full Text] [Related]
[Next]
